The expanding field of targeted treatment relies heavily on recombinant cytokine technology, and a precise understanding of individual profiles is paramount for refining experimental design and therapeutic efficacy. Specifically, examining the attributes of recombinant IL-1A, IL-1B, IL-2, and IL-3 reveals notable differences in their molecular make